Patriot Financial Group Insurance Agency LLC Has $1.14 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Share on StockTwits

Patriot Financial Group Insurance Agency LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 5.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,061 shares of the life sciences company’s stock after acquiring an additional 145 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Illumina were worth $1,137,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ILMN. Thoroughbred Financial Services LLC raised its position in shares of Illumina by 38,516.8% during the second quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock worth $87,583,000 after acquiring an additional 873,560 shares during the last quarter. American Century Companies Inc. raised its position in shares of Illumina by 107.1% during the first quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock worth $253,484,000 after acquiring an additional 421,953 shares during the last quarter. Jennison Associates LLC raised its position in shares of Illumina by 5.2% during the second quarter. Jennison Associates LLC now owns 5,976,219 shares of the life sciences company’s stock worth $2,200,145,000 after acquiring an additional 296,541 shares during the last quarter. Nikko Asset Management Americas Inc. raised its position in shares of Illumina by 242.2% during the second quarter. Nikko Asset Management Americas Inc. now owns 416,303 shares of the life sciences company’s stock worth $153,262,000 after acquiring an additional 294,643 shares during the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd raised its position in shares of Illumina by 841.1% during the first quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 269,170 shares of the life sciences company’s stock worth $83,628,000 after acquiring an additional 240,569 shares during the last quarter. Institutional investors own 92.09% of the company’s stock.

In related news, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $349.28, for a total value of $3,492,800.00. Following the completion of the sale, the senior vice president now owns 65,994 shares in the company, valued at $23,050,384.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $376.50, for a total value of $1,242,450.00. Following the completion of the sale, the director now owns 272,616 shares of the company’s stock, valued at approximately $102,639,924. The disclosure for this sale can be found here. Insiders sold 60,458 shares of company stock valued at $19,329,754 in the last quarter. 0.38% of the stock is currently owned by corporate insiders.

ILMN has been the subject of a number of recent research reports. ValuEngine upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Piper Jaffray Companies dropped their target price on Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a research report on Tuesday, July 30th. Credit Suisse Group restated a “buy” rating and set a $340.00 target price on shares of Illumina in a research report on Wednesday, July 31st. Argus dropped their target price on Illumina to $340.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Finally, UBS Group boosted their target price on Illumina from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $330.92.

NASDAQ ILMN traded down $9.08 on Friday, reaching $279.44. The company had a trading volume of 995,369 shares, compared to its average volume of 987,484. The stock’s 50 day moving average is $306.60 and its 200-day moving average is $315.14. The stock has a market cap of $42.42 billion, a price-to-earnings ratio of 48.85, a PEG ratio of 2.69 and a beta of 1.10. The company has a quick ratio of 6.10, a current ratio of 6.79 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 52 week low of $268.62 and a 52 week high of $380.76.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $838.00 million during the quarter, compared to the consensus estimate of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The firm’s revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.43 earnings per share. As a group, analysts forecast that Illumina, Inc. will post 6.04 EPS for the current year.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Further Reading: How is a price target determined?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.